Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years With Attention-deficit/Hyperactivity Disorder

NCT03610464 is registered in ClinicalTrials.gov with Tris Pharma, Inc. as lead sponsor.

NCT NCT03610464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03610464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years With Attention-deficit/Hyperactivity Disorder
Lead sponsor
Tris Pharma, Inc.
Phase
Phase 4
Overall status
Completed
Start date
May 7, 2018
Completion date
May 23, 2018
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder